|Chennai||Rs. 24840.00 (-0.36%)|
|Mumbai||Rs. 25460.00 (-0.16%)|
|Delhi||Rs. 25450.00 (2.21%)|
|Kolkata||Rs. 25000.00 (0%)|
|Kerala||Rs. 24700.00 (0%)|
|Bangalore||Rs. 25050.00 (1.42%)|
|Hyderabad||Rs. 24930.00 (1.63%)|
Delphi Genetics announced today during a presentation at the 34th Annual Meeting of the Molecular Biology Society of Japan that it has established the complete chromosome sequence of all the strains sold in the research kits of the company. The complete genome sequencing of the strains of Escherichia coli (E. coli) sold for use in research is a world first and will ensure researchers of working on a routine basis with material that is completely genetically defined. Strains of E. coli are used on a daily basis in laboratories to create genes assembling and produce recombinant proteins. Over the past 20 years, these strains have been integrated into molecular biology products in the form of kits sold to academic and private researchers. These strains can mutate and therefore derive ; several of them have the same name even if they are different on a genetic level. Therefore, with complete sequencing it is possible to perfectly characterise the material used in the experiments. To create complete genome sequences, Delphi Genetics has invested in the latest generation sequencing platform.
Philippe Gabant, founder and business development director of Delphi Genetics explains: “Thanks to the complete genetic information of the strains present in our kits, we can ensure researchers of having products that are completely characterised on a genomic level. This is essential for them to be able to compare their results and also, in certain cases, to fully interpret them. The determination of the genome sequences of the strains present in our research kits, demonstrates Delphi Genetics’ desire to focus its development on leading-edge genetic products that meet a constantly evolving scientific demand.”
Delphi Genetics has been marketing innovative kits for researchers since 2004. Some of these kits contain technologies that have since been licensed for industrial applications; in 2009 Delphi Genetics announced a non-exclusive licence agreement with Sanofi-Pasteur, the human vaccine division of Sanofi-Aventis and a non-exclusive agreement with GSK in 2010. These agreements allow Sanofi-Pasteur and GSK to implement the Staby Express technology in productions of recombinant proteins, thus enabling them to produce a high yield without using antibiotics.
About Delphi Genetics SA
Founded at the end of 2001, Delphi Genetics SA develops innovative research kits and more efficient technologies for genetic engineering and the expression of proteins in bacteria by using an expertise unique in the domain of plasmid stabilisation systems. For more information, visit our website: www.delphigenetics.com.